NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Forecast & News

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

GRIFOLS S A/S announced a semi-annual dividend on Thursday, October 31st. Stockholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a dividend yield of 1.3%. The ex-dividend date is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's Dividend History.

GRIFOLS S A/S's stock split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were distributed to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for GRIFOLS S A/S.

4 brokers have issued 12-month price objectives for GRIFOLS S A/S's stock. Their forecasts range from $19.00 to $22.50. On average, they anticipate GRIFOLS S A/S's stock price to reach $20.75 in the next year. This suggests that the stock has a possible downside of 9.7%. View Analyst Price Targets for GRIFOLS S A/S.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GRIFOLS S A/S.

Media coverage about GRFS stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for GRIFOLS S A/S.

GRIFOLS S A/S saw a decline in short interest in the month of October. As of October 15th, there was short interest totalling 2,490,000 shares, a decline of 7.4% from the September 15th total of 2,690,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.0% of the shares of the stock are short sold. View GRIFOLS S A/S's Current Options Chain.

Some companies that are related to GRIFOLS S A/S include Allergan (AGN), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG) and Teva Pharmaceutical Industries (TEVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Allergan (AGN), Teva Pharmaceutical Industries (TEVA), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), Southern Copper (SCCO), Celgene (CELG), NVIDIA (NVDA), Supernus Pharmaceuticals (SUPN) and Alibaba Group (BABA).

GRIFOLS S A/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Pictet Asset Management Ltd. (1.15%), First Trust Advisors LP (0.40%), Soros Fund Management LLC (0.30%), Millennium Management LLC (0.29%), Man Group plc (0.22%) and Beck Mack & Oliver LLC (0.17%).

GRFS stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Banco de Sabadell S.A, Soros Fund Management LLC, CWM LLC, Beck Mack & Oliver LLC, CIBC Asset Management Inc, Lenox Wealth Management Inc. and Crossmark Global Holdings Inc..

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Pictet Asset Management Ltd., Point72 Asset Management L.P., Barclays PLC, CIBC Private Wealth Group LLC, Squarepoint Ops LLC, Voloridge Investment Management LLC and State Street Corp.

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GRFS stock can currently be purchased for approximately $22.97.

GRIFOLS S A/S has a market capitalization of $15.79 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S.

The official website for GRIFOLS S A/S is http://www.grifols.com/.

GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected]